Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    David Siegel, PhD

    TitlePostdoctoral Scholar
    SchoolUCSF School of Medicine
    DepartmentMedicine
    Address1550 4th Street, Bldg 19B
    San Francisco CA 94158
    Phone415-502-2027
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      University of California, BerkeleyPhDPhysics2012
      Cornell UniversityBAPhysics and Mathematics2005

      Collapse Overview 
      Collapse Overview
      David Siegel is a bioinformatics postdoc in the Noah Zaitlen group at UCSF.


      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Bloudek L, Roy A, Kish JK, Siegel DS, Jagannath S, Globe D, Orloski L, Kuriakose ET. Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model. J Manag Care Spec Pharm. 2016 Aug; 22(8):991-1002. PMID: 27459662.
        View in: PubMed
      2. Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špicka I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016 Sep 1; 128(9):1174-80. PMID: 27439911.
        View in: PubMed
      3. Jagannath S, Roy A, Kish J, Lunacsek O, Globe D, Eaddy M, Kuriakose ET, Willey J, Butler-Bird S, Siegel D. Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices. Expert Rev Hematol. 2016 Jul; 9(7):707-17. PMID: 27291638.
        View in: PubMed
      4. Ghobrial IM, Siegel DS, Vij R, Berdeja JG, Richardson PG, Neuwirth R, Patel CG, Zohren F, Wolf JL. TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia. Am J Hematol. 2016 Jun; 91(4):400-5. PMID: 26800393.
        View in: PubMed
      5. Lee SJ, Levitsky K, Parlati F, Bennett MK, Arastu-Kapur S, Kellerman L, Woo TF, Wong AF, Papadopoulos KP, Niesvizky R, Badros AZ, Vij R, Jagannath S, Siegel D, Wang M, Ahmann GJ, Kirk CJ. Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay. Br J Haematol. 2016 Jun; 173(6):884-95. PMID: 27071340.
        View in: PubMed
      6. Siegel DS, Dimopoulos M, Jagannath S, Goldschmidt H, Durrant S, Kaufman JL, Leleu X, Nagler A, Offner F, Graef T, Eid JE, Houp J, Gause C, Vuocolo S, Anderson KC. VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2016 Jun; 16(6):329-334.e1. PMID: 27025160.
        View in: PubMed
      7. Jurczyszyn A, Olszewska-Szopa M, Vesole AS, Vesole DH, Siegel DS, Richardson PG, Paba-Prada C, Callander NS, Huras H, Skotnicki AB. Multiple Myeloma in Pregnancy-A Review of the Literature and a Case Series. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):e39-45. PMID: 26847816.
        View in: PubMed
      8. Squifflet P, Michiels S, Siegel D, Vij R, Jagannath S, Saad ED, Rajangam K, Ro SK, Buyse M. Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2015 Nov; 15(11):680-6. PMID: 26482107.
        View in: PubMed
      9. DA Siegel, F El Gabaly, KF McCarty, NC Bartelt. . In situ characterization of the formation of a mixed conducting phase on the surface of yttria-stabilized zirconia near Pt electrodes. Physical Review B. 2015; 92(12):125421.
      10. Roy A, Kish JK, Bloudek L, Siegel DS, Jagannath S, Globe D, Kuriakose ET, Migliaccio-Walle K. Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework. Am Health Drug Benefits. 2015 Jun; 8(4):204-15. PMID: 26157542; PMCID: PMC4489189.
      11. Vesole DH, Bilotti E, Richter JR, McNeill A, McBride L, Raucci L, Anand P, Bednarz U, Ivanovski K, Smith J, Batra V, Aleman A, Sims T, Guerrero L, Mato A, Siegel DS. Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Br J Haematol. 2015 Oct; 171(1):52-9. PMID: 26018491.
        View in: PubMed
      12. Vij R, Wang M, Jagannath S, Niesvizky R, Jakubowiak AJ, Kavalerchik E, Huang M, Siegel DS. Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma. Leuk Lymphoma. 2015 Oct; 56(10):2959-61. PMID: 25699653.
        View in: PubMed
      13. Vesole DH, Siegel DS. Counterpoints: Do patients with multiple myeloma need maintenance treatment? No, maintenance treatment should not be used outside clinical trials. Clin Adv Hematol Oncol. 2015 Mar; 13(3):163, 167-9. PMID: 26352424.
        View in: PubMed
      14. Vesole DH, Siegel DS. Pretransplant induction regimens for multiple myeloma. Biol Blood Marrow Transplant. 2015 Feb; 21(2):200-1. PMID: 25534538.
        View in: PubMed
      15. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špicka I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015 Jan 8; 372(2):142-52. PMID: 25482145.
        View in: PubMed
      16. Liu L, Siegel DA, Chen W, Liu P, Guo J, Duscher G, Zhao C, Wang H, Wang W, Bai X, McCarty KF, Zhang Z, Gu G. Unusual role of epilayer-substrate interactions in determining orientational relations in van der Waals epitaxy. Proc Natl Acad Sci U S A. 2014 Nov 25; 111(47):16670-5. PMID: 25385622; PMCID: PMC4250159.
      17. Choongyu Hwang, Duck Young Kim, David A Siegel, Kevin T Chan, Jesse Noffsinger, Alexei V Fedorov, Marvin L Cohen, Börje Johansson, Jeffrey B Neaton, Alessandra Lanzara. . Ytterbium-driven strong enhancement of electron-phonon coupling in graphene. Physical Review B. 2014; 90(11):115417.
      18. Papadopoulos KP, Siegel DS, Vesole DH, Lee P, Rosen ST, Zojwalla N, Holahan JR, Lee S, Wang Z, Badros A. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. J Clin Oncol. 2015 Mar 1; 33(7):732-9. PMID: 25225420.
        View in: PubMed
      19. Kevin F McCarty, Matteo Monti, Shu Nie, David A Siegel, Elena Starodub, Farid El Gabaly, Anthony H McDaniel, Andrey Shavorskiy, Tolek Tyliszczak, Hendrik Bluhm, Norman C Bartelt, Juan de la Figuera. . Oxidation of magnetite (100) to hematite observed by in situ spectroscopy and microscopy. The Journal of Physical Chemistry C. 2014; 118(34):19768-19777.
      20. Siegel DS. Reply to "The challenge of cross-trial comparison using limited data" Haematologica. 2014;99(8):e000. Haematologica. 2014 Aug; 99(8):e147. PMID: 25082788; PMCID: PMC4116849.
      21. Donato ML, Siegel DS, Vesole DH, McKiernan P, Nyirenda T, Pecora AL, Baker M, Goldberg SL, Mato A, Goy A, Rowley SD. The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation. Biol Blood Marrow Transplant. 2014 Aug; 20(8):1211-6. PMID: 24792872.
        View in: PubMed
      22. Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson KC. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014 Mar 20; 123(12):1826-32. PMID: 24421329; PMCID: PMC3962162.
      23. Liu L, Park J, Siegel DA, McCarty KF, Clark KW, Deng W, Basile L, Idrobo JC, Li AP, Gu G. Heteroepitaxial growth of two-dimensional hexagonal boron nitride templated by graphene edges. Science. 2014 Jan 10; 343(6167):163-7. PMID: 24408431.
        View in: PubMed
      24. Siegel DS. Managing adverse events of multiple myeloma and anti-multiple myeloma treatment: a perspective on carfilzomib. Oncology (Williston Park). 2013 Dec; 27 Suppl 3:2-3. PMID: 25184229.
        View in: PubMed
      25. Siegel DS. From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma. Ther Adv Hematol. 2013 Dec; 4(6):354-65. PMID: 24319571; PMCID: PMC3854560.
      26. Wang TP, Safran SG, Richter JR, Siegel DS, Vesole DH. Subepithelial corneal immunoglobulin deposition as a manifestation of multiple myeloma: a case report and literature review. Clin Lymphoma Myeloma Leuk. 2014 Feb; 14(1):e39-42. PMID: 24211225.
        View in: PubMed
      27. Kaufman JL, Niesvizky R, Stadtmauer EA, Chanan-Khan A, Siegel D, Horne H, Wegener WA, Goldenberg DM. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. Br J Haematol. 2013 Nov; 163(4):478-86. PMID: 24112026.
        View in: PubMed
      28. Siegel DA, Chueh WC, El Gabaly F, McCarty KF, de la Figuera J, Blanco-Rey M. Determination of the surface structure of CeO2(111) by low-energy electron diffraction. J Chem Phys. 2013 Sep 21; 139(11):114703. PMID: 24070301.
        View in: PubMed
      29. Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt H, Hungria V, Spencer A, Palumbo A, Graef T, Eid JE, Houp J, Sun L, Vuocolo S, Anderson KC. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 2013 Oct; 14(11):1129-40. PMID: 24055414.
        View in: PubMed
      30. San-Miguel JF, Richardson PG, Günther A, Sezer O, Siegel D, Bladé J, LeBlanc R, Sutherland H, Sopala M, Mishra KK, Mu S, Bourquelot PM, Victoria Mateos M, Anderson KC. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2013 Oct 10; 31(29):3696-703. PMID: 24019544.
        View in: PubMed
      31. Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Huang M, Orlowski RZ, Niesvizky R. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood. 2013 Oct 31; 122(18):3122-8. PMID: 24014245; PMCID: PMC3814729.
      32. Cohen-Wolkowiez M, Sampson M, Bloom BT, Arrieta A, Wynn JL, Martz K, Harper B, Kearns GL, Capparelli EV, Siegel D, Benjamin DK, Smith PB. Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants. Pediatr Infect Dis J. 2013 Sep; 32(9):956-61. PMID: 23587979; PMCID: PMC3769518.
      33. Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCulloch L, Rajangam K, Lonial S. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013 Nov; 98(11):1753-61. PMID: 23935022; PMCID: PMC3815177.
      34. Nie S, Starodub E, Monti M, Siegel DA, Vergara L, El Gabaly F, Bartelt NC, de la Figuera J, McCarty KF. Insight into magnetite's redox catalysis from observing surface morphology during oxidation. J Am Chem Soc. 2013 Jul 10; 135(27):10091-8. PMID: 23763580.
        View in: PubMed
      35. Hajek R, Siegel D, Orlowski RZ, Ludwig H, Palumbo A, Dimopoulos M. The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma. 2014 Jan; 55(1):11-8. PMID: 23614765.
        View in: PubMed
      36. Siegel DA, Regan W, Fedorov AV, Zettl A, Lanzara A. Charge-carrier screening in single-layer graphene. Phys Rev Lett. 2013 Apr 5; 110(14):146802. PMID: 25167021.
        View in: PubMed
      37. Niesvizky R, Martin TG, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, Wong AF, Lee S, Orlowski RZ, Wang M. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res. 2013 Apr 15; 19(8):2248-56. PMID: 23447001; PMCID: PMC4149337.
      38. Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J, Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N, McBride L, Bilotti E, Anand P, Nardelli L, Wear S, Larkins G, Chen M, Zaki MH, Jacques C, Anderson KC. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013 Mar 14; 121(11):1961-7. PMID: 23243282; PMCID: PMC4123324.
      39. Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, Wong A, Orlowski RZ, Siegel DS. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):310-8. PMID: 23040437.
        View in: PubMed
      40. David A Siegel, Choongyu Hwang, Alexei V Fedorov, Alessandra Lanzara. . Electron–phonon coupling and intrinsic bandgap in highly-screened graphene. New Journal of Physics. 2012; 14(9):095006.
      41. Choongyu Hwang, David A Siegel, Sung-Kwan Mo, William Regan, Ariel Ismach, Yuegang Zhang, Alex Zettl, Alessandra Lanzara. . Fermi velocity engineering in graphene by substrate modification. Scientific reports. 2012; 2:590.
      42. Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012 Sep; 158(6):739-48. PMID: 22845873.
        View in: PubMed
      43. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012 Oct 4; 120(14):2817-25. PMID: 22833546; PMCID: PMC4123387.
      44. Siegel DS. Relapsed/Refractory multiple myeloma: defining refractory disease and identifying strategies to overcome resistance. Semin Hematol. 2012 Jul; 49 Suppl 1:S3-15. PMID: 22727390.
        View in: PubMed
      45. Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012 Jun 14; 119(24):5661-70. PMID: 22555973; PMCID: PMC4123327.
      46. Wolf JL, Siegel D, Goldschmidt H, Hazell K, Bourquelot PM, Bengoudifa BR, Matous J, Vij R, de Magalhaes-Silverman M, Abonour R, Anderson KC, Lonial S. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012 Sep; 53(9):1820-3. PMID: 22288662.
        View in: PubMed
      47. Tufail M, Siegel DS, McBride L, Bilotti E, Bello E, Anand P, Olivo K, Bendarz U, McNeill A, Vesole DH. Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012 Jun; 12(3):186-90. PMID: 22381702.
        View in: PubMed
      48. Mato A, Feldman T, Richter J, Siegel DS, Goy A. Liquid tumors in the elderly. Clin Geriatr Med. 2012 Feb; 28(1):115-52. PMID: 22326039.
        View in: PubMed
      49. Jakubowiak AJ, Benson DM, Bensinger W, Siegel DS, Zimmerman TM, Mohrbacher A, Richardson PG, Afar DE, Singhal AK, Anderson KC. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2012 Jun 1; 30(16):1960-5. PMID: 22291084.
        View in: PubMed
      50. Choongyu Hwang, Cheol-Hwan Park, David A Siegel, Alexei V Fedorov, Steven G Louie, Alessandra Lanzara. . Direct measurement of quantum phases in graphene via photoemission spectroscopy. Physical Review B. 2011; 84(12):125422.
      51. Jacobus SJ, Kumar S, Uno H, Van Wier SA, Ahmann GJ, Henderson KJ, Callander NS, Williams ME, Siegel DS, Greipp PR, Rajkumar SV, Fonseca R. Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03. Br J Haematol. 2011 Nov; 155(3):340-8. PMID: 21902684; PMCID: PMC3192237.
      52. Kumar SK, Uno H, Jacobus SJ, Van Wier SA, Ahmann GJ, Henderson KJ, Callander NS, Haug JL, Siegel DS, Greipp PR, Fonseca R, Rajkumar SV. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2011 Oct 20; 118(16):4359-62. PMID: 21860025; PMCID: PMC3204907.
      53. Siegel D, Jagannath S, Vesole DH, Borello I, Mazumder A, Mitsiades C, Goddard J, Dunbar J, Normant E, Adams J, Grayzel D, Anderson KC, Richardson P. A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. Leuk Lymphoma. 2011 Dec; 52(12):2308-15. PMID: 21851215.
        View in: PubMed
      54. Siegel DA, Park CH, Hwang C, Deslippe J, Fedorov AV, Louie SG, Lanzara A. Many-body interactions in quasi-freestanding graphene. Proc Natl Acad Sci U S A. 2011 Jul 12; 108(28):11365-9. PMID: 21709258; PMCID: PMC3136305.
      55. Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, Jagannath S, Siegel D, Keith Stewart A, Wang L, Orlowski RZ, Belch A, Jakubowiak A, Somlo G, Trudel S, Bahlis N, Lonial S, Singhal S, Kukreti V, Tricot G. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol. 2011 Jun; 86(6):484-7. PMID: 21477075.
        View in: PubMed
      56. Siegel DS, Vij R, Jakubowiak AJ. Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma. Clin Adv Hematol Oncol. 2011 Apr; 9(4):1-15. PMID: 21928467.
        View in: PubMed
      57. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011 May 5; 117(18):4691-5. PMID: 21292775; PMCID: PMC3710442.
      58. San-Miguel JF, Dimopoulos MA, Stadtmauer EA, Rajkumar SV, Siegel D, Bravo ML, Olesnyckyj M, Knight RD, Zeldis JB, Harousseau JL, Weber DM. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):38-43. PMID: 21273172.
        View in: PubMed
      59. David A Siegel, CG Hwang, Alexei V Fedorov, Alessandra Lanzara. . Quasifreestanding multilayer graphene films on the carbon face of SiC. Physical Review B. 2010; 81(24):241417.
      60. Tong WG, Chen R, Plunkett W, Siegel D, Sinha R, Harvey RD, Badros AZ, Popplewell L, Coutre S, Fox JA, Mahadocon K, Chen T, Kegley P, Hoch U, Wierda WG. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol. 2010 Jun 20; 28(18):3015-22. PMID: 20479412.
        View in: PubMed
      61. SD Lounis, DA Siegel, R Broesler, CG Hwang, EE Haller, A Lanzara. . Resonant photoluminescent charging of epitaxial graphene. Applied Physics Letters. 2010; 96(15):151913.
      62. Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA. Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4. PMID: 20118399; PMCID: PMC2813833.
      63. David A Siegel, SY Zhou, F El Gabaly, Andreas K Schmid, Kevin F McCarty, Alessandra Lanzara. . Three-fold diffraction symmetry in epitaxial graphene and the SiC substrate. Physical Review B. 2009; 80(24):241407.
      64. Sprinkle M, Siegel D, Hu Y, Hicks J, Tejeda A, Taleb-Ibrahimi A, Le Fèvre P, Bertran F, Vizzini S, Enriquez H, Chiang S, Soukiassian P, Berger C, de Heer WA, Lanzara A, Conrad EH. First direct observation of a nearly ideal graphene band structure. Phys Rev Lett. 2009 Nov 27; 103(22):226803. PMID: 20366119.
        View in: PubMed
      65. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel DS, Katz M, Greipp PR. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010 Jan; 11(1):29-37. PMID: 19853510; PMCID: PMC3042271.
      66. SY Zhou, ÇÖ Girit, A Scholl, CJ Jozwiak, DA Siegel, P Yu, JT Robinson, F Wang, A Zettl, A Lanzara. . Instability of two-dimensional graphene: Breaking s p 2 bonds with soft x rays. Physical Review B. 2009; 80(12):121409.
      67. Chen C, Reece DE, Siegel D, Niesvizky R, Boccia RV, Stadtmauer EA, Abonour R, Richardson P, Matous J, Kumar S, Bahlis NJ, Alsina M, Vescio R, Coutre SE, Pietronigro D, Knight RD, Zeldis JB, Rajkumar V. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol. 2009 Jul; 146(2):164-70. PMID: 19545290; PMCID: PMC2728892.
      68. Hyunyong Choi, Ferenc Borondics, David A Siegel, Shuyun Y Zhou, Michael C Martin, Alessandra Lanzara, Robert A Kaindl. . Broadband electromagnetic response and ultrafast dynamics of few-layer epitaxial graphene. Applied Physics Letters. 2009; 94(17):172102.
      69. David A Siegel, Shuyun Y Zhou, Farid El Gabaly, Alexei V Fedorov, Andreas K Schmid, Alessandra Lanzara. . Self-doping effects in epitaxially grown graphene. Applied Physics Letters. 2008; 93(24):243119.
      70. SY Zhou, DA Siegel, AV Fedorov, A Lanzara. . Kohn anomaly and interplay of electron-electron and electron-phonon interactions in epitaxial graphene. Physical Review B. 2008; 78(19):193404.
      71. Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Esseltine DL, Anderson KC. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008 Nov; 143(4):537-40. PMID: 18783399.
        View in: PubMed
      72. Zhou SY, Siegel DA, Fedorov AV, Lanzara A. Metal to insulator transition in epitaxial graphene induced by molecular doping. Phys Rev Lett. 2008 Aug 22; 101(8):086402. PMID: 18764644.
        View in: PubMed
      73. SY Zhou, DA Siegel, AV Fedorov, A Lanzara. . Departure from the conical dispersion in epitaxial graphene. Physica E: Low-dimensional Systems and Nanostructures. 2008; 40(7):2642-2647.
      74. SY Zhou, DA Siegel, AV Fedorov, F El Gabaly, AK Schmid, AH Castro Neto, D-H Lee, A Lanzara. . Origin of the energy bandgap in epitaxial graphene. Nature Materials. 2008; 7(4):259-260.
      75. Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, Sun L, Ricker J, Rizvi S, Oerth C, Atkins B, Fearen I, Anderson K, Siegel D. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma. 2008 Mar; 49(3):502-7. PMID: 18297527.
        View in: PubMed
      76. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007 Nov 22; 357(21):2133-42. PMID: 18032763.
        View in: PubMed
      77. Stadtmauer EA, Lonial S, Vesole DH, Abonour R, Alsina M, Badros A, Comenzo R, Durie B, Giralt S, Hussein M, Jakubowiak A, Mehta J, Niesvizky R, Orlowski R, Siegel D, Singhal S, Vescio R, Wang M, Zangari M, Munshi NC. A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. Clin Adv Hematol Oncol. 2007 Oct; 5(10 Suppl 15):7-19, quiz 21-2. PMID: 18000495.
        View in: PubMed
      78. Berenson JR, Boccia R, Siegel D, Bozdech M, Bessudo A, Stadtmauer E, Talisman Pomeroy J, Steis R, Flam M, Lutzky J, Jilani S, Volk J, Wong SF, Moss R, Patel R, Ferretti D, Russell K, Louie R, Yeh HS, Swift RA. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol. 2006 Oct; 135(2):174-83. PMID: 17010047.
        View in: PubMed
      79. Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J, Shaughnessy JD, Jagannath S, Bolejack V, Gurley J, Hoering A, Vesole D, Desikan R, Siegel D, Mehta J, Singhal S, Munshi NC, Dhodapkar M, Jenkins B, Attal M, Harousseau JL, Crowley J. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol. 2006 Oct; 135(2):158-64. PMID: 16939489.
        View in: PubMed
      80. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006 Jul 1; 24(19):3113-20. PMID: 16754936.
        View in: PubMed
      81. Fassas AB, Barlogie B, Ward S, Jagannath S, Vesole D, Mattox S, Siegel D, Muwalla F, Zangari M, Anaissie E, Rhee FV, Thertulien R, Lee CK, Desikan R, Arzumanian V, McCoy J, Tricot G. Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience. Br J Haematol. 2003 Nov; 123(3):484-9. PMID: 14617011.
        View in: PubMed
      82. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26; 348(26):2609-17. PMID: 12826635.
        View in: PubMed
      83. Shaughnessy J, Jacobson J, Sawyer J, McCoy J, Fassas A, Zhan F, Bumm K, Epstein J, Anaissie E, Jagannath S, Vesole D, Siegel D, Desikan R, Munshi N, Badros A, Tian E, Zangari M, Tricot G, Crowley J, Barlogie B. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood. 2003 May 15; 101(10):3849-56. PMID: 12531801.
        View in: PubMed
      84. Fassas AB, Muwalla F, Berryman T, Benramdane R, Joseph L, Anaissie E, Sethi R, Desikan R, Siegel D, Badros A, Toor A, Zangari M, Morris C, Angtuaco E, Mathew S, Wilson C, Hough A, Harik S, Barlogie B, Tricot G. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol. 2002 Apr; 117(1):103-8. PMID: 11918539.
        View in: PubMed
      85. Niesvizkya R, Choy CG, Siegel D, Lyons L, Michaeli J. Extended survival in advanced-stage multiple myeloma patients treated with gallium nitrate. Leuk Lymphoma. 2002 Mar; 43(3):603-5. PMID: 12002765.
        View in: PubMed
      86. Niesvizky R, Siegel D, Glassman J, Straus D, Fine J, Lyons L, Michaeli J. Impact of early response to sequential high-dose chemotherapy on outcome of patients with advanced myeloma and poor prognostic features. Leuk Lymphoma. 2002 Mar; 43(3):607-12. PMID: 12002766.
        View in: PubMed
      David's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Back to TOP